Posted by Michael Wonder on 24 Jan 2025
Australia’s TGA approves registration of CSL’s Andembry (garadacimab) for the prevention of recurrent hereditary angioedema attacks
24 January 2025 - This regulatory approval for registration in Australia is the first in the world for Andembry.
CSL today announced that the Australian TGA has approved the registration of Andembry (garadacimab) for routine prevention of recurrent hereditary angioedema attacks in patients aged 12 years and older with C1-esterase inhibitor deficiency or dysfunction.
